Potential Benefit of Curcumin Adjuvant Therapy to the Standard H. Pylori Eradication Therapy in Patients With Peptic Ulcer Disease

Abstract

Objective: This study was designed to explore the benefit of curcumin as adjuvant therapy to the standard Helicobacter pylori eradication triple therapy in both duodenal and gastric ulcers patients.Methods: The present study enrolled 40 patients newly diagnosed endoscopically with peptic ulcer disease to be allocated into group 1 treated with standard H. pylori eradication triple therapy, and group 2 patients treated with curcumin (500 mg) capsules three times daily for 14 days as an adjuvant to standard triple therapy. Stool antigen test, immunoglobulin M serology test, tumor necrosis factor-alpha (TNF-α), interleukin 1 beta (IL-1β), and total antioxidant capacity (T-AOC) are measured at the baseline and after 6 weeks of treatment. Results:The result showed that the use of curcumin as adjuvant therapy produced highly significant improvement in healing efficacy which was significantly distinguished in duodenal ulcer patients compared to gastric ulcer groups 2 patients (p<0.05), along with a highly significant reduction in pro-inflammatory IL-1β level in group 2 patients (p<0.01). After 6 weeks of treatment, there was a highly significant elevation in the level of TNF-α in groups 1 (p<0.01), though group 2 patients presented with non-significant elevation in TNF-α level. Moreover, the T-AOC was improved with curcumin adjuvant therapy, though non-significant, compared to group 1 patients who showed a reduction in T-AOC. Conclusion:This study revealed that addition of curcumin as adjuvant therapy produced improvement in ulcer healing efficacy, and controlled the inflammatory and oxidative stress process induced by H. pylori infection.

The Effect of Probiotic Supplement as Adjuvant Therapy on Dyspeptic Symptoms and Quality of Life during Helicobacter pylori Eradication Therapy in a Sample of Iraqi Patients with Peptic Ulcer Disease

“…Figure (1): Comparison of QOL mean scores of the SF-8 questionnaire in study groups patient's pre and post-treatment Discussion Demographic Data and Disease Characteristics of Patients with H. pylori Induced Peptic Ulcer DiseaseIn the present study and in other studies, both genders have a higher rate of infection with H. pylori microrganism with slight predominance towards male patients in this study and others[10,11] , or towards female gender in other studies[12][13][14] . Moreover, H. pylori infection mostly presents within (21-40) years age groups in this study, and a lower prevalence rate of H. pylori infection was noticed in the elderly among all study groups.…”

“…After 8 weeks of treatment, there was highly significant increase in the eight domains of the SF-8 score (PF, RP, BP, GH, VT, SF, RE, MH, PCS and MCS) in all 4 groups compared to pretreatment (P˂0.01), but no significant difference between the study groups after treatment was noticed (P˃0.05) (Figure 1) In the present study and in other studies, both genders have a higher rate of infection with H. pylori microrganism with slight predominance towards male patients in this study and others [10,11] , or towards female gender in other studies [12][13][14] . Moreover, H. pylori infection mostly presents within (21-40) years age groups in this study, and a lower prevalence rate of H. pylori infection was noticed in the elderly among all study groups.…”

Is Curcumin Intake Really Effective for Chronic Inflammatory Metabolic Disease? A Review of Meta-Analyses of Randomized Controlled Trials

“…A meta-analysis of RCTs by Dehzad et al 2023 [42] showed the anti-inflammatory effect of curcumin/curcuminoids/turmeric. Subjects taking 60-2000 mg/day of curcumin or 150-1500 mg/day of curcuminoids or 900-3000 mg/day of turmeric showed reductions in CRP [weighted mean difference (WMD) = −0.58 mg/L; 95% confidence interval (CI) −0.74 to −0.41; I 2 = 98.9%; p < 0.001], TNF-α (WMD = −3.48 pg/mL; 95% CI −4.38 to −2.58; I 2 = 99.4%; p < 0.001) and IL-6 (WMD = −1.31 pg/mL; 95% CI −1.58 to −0.67; I 2 = 88.2%, p < 0.001), with no difference in interleukin 1β (IL-1β) (WMD = −0.46 pg/mL; 95% CI −1.18 to 0.27; I 2 = 75.8%; p < 0.001) in 46 publications [23,29,38, for CRP, 23 publications [24,43,47,48,50,[54][55][56]60,63,64,67,68,71,79,83,[86][87][88][89][90][91][92] for TNF-α, and 20 publications for IL-6 [23,24,[45][46][47][48]50,54,63,64,68,83,86,89,91,[93]…”

Role of Turmeric and Curcumin in Prevention and Treatment of Chronic Diseases: Lessons Learned from Clinical Trials

“…It was also shown to improve dyspeptic symptoms and reduce gastric inflammation in these patients . Administration of 500–1500 mg/day curcumin with piperine for 4 weeks in patients infected with H. pyroli was found to be safe and suppressed dyspepsia symptoms. , …”

“…394 Administration of 500−1500 mg/day curcumin with piperine for 4 weeks in patients infected with H. pyroli was found to be safe and suppressed dyspepsia symptoms. 395,396 4.2.7. Turmeric and curcumin in Inflammatory Disorders.…”